Northern Trust Corp Grows Stake in Aadi Bioscience, Inc. (NASDAQ:AADI)

Northern Trust Corp grew its holdings in Aadi Bioscience, Inc. (NASDAQ:AADI) by 33.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 91,151 shares of the company’s stock after acquiring an additional 22,677 shares during the quarter. Northern Trust Corp owned about 0.37% of Aadi Bioscience worth $288,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in AADI. Peapod Lane Capital LLC purchased a new position in shares of Aadi Bioscience in the 4th quarter valued at about $1,397,000. BML Capital Management LLC boosted its position in shares of Aadi Bioscience by 5.0% in the 4th quarter. BML Capital Management LLC now owns 2,100,000 shares of the company’s stock valued at $6,626,000 after purchasing an additional 100,000 shares during the period. Geode Capital Management LLC boosted its position in shares of Aadi Bioscience by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 217,294 shares of the company’s stock valued at $686,000 after purchasing an additional 8,546 shares during the period. Finally, QVT Financial LP acquired a new stake in shares of Aadi Bioscience in the 4th quarter valued at about $7,300,000. Hedge funds and other institutional investors own 52.08% of the company’s stock.

Aadi Bioscience Stock Down 6.1%

Shares of NASDAQ AADI opened at $1.69 on Monday. The stock has a market cap of $41.74 million, a PE ratio of -0.74 and a beta of 0.68. Aadi Bioscience, Inc. has a 52-week low of $1.21 and a 52-week high of $3.81. The business has a 50-day moving average price of $1.68 and a 200 day moving average price of $2.30.

Aadi Bioscience (NASDAQ:AADI) last announced its earnings results on Tuesday, March 18th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.37). The firm had revenue of $7.24 million during the quarter, compared to analyst estimates of $7.45 million. Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%. Sell-side analysts anticipate that Aadi Bioscience, Inc. will post -2.04 earnings per share for the current year.

Aadi Bioscience Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.